Voyager Therapeutics Cash Flow - Quarterly (NASDAQ:VYGR)

Add to My Stocks
$21.77 $0.34 (1.59%) VYGR stock closing price Jun 19, 2018 (Closing)

The Voyager Therapeutics cash flow statement is one of the important reports considered by investors doing a fundamental analysis of the company. The profit-loss statement shows Voyager Therapeutics profits, the balance sheet shows Voyager Therapeutics debt, and the cash flow statement reflects the liquidity and solvency of a firm. This statement reflects the company's ability to generate cash flows. Voyager Therapeutics had cash and cash equivalents of $36.64M at beginning of the quarter and $141.1M at quarter end of 2018 Q1. Voyager Therapeutics cash flow analysis tells whether or not the company has enough cash for its day to day activities, and for investing for future growth. VYGR increase in investments stood at a value of $58.4M for the latest quarter 2018 Q1.

View and download details of Voyager Therapeutics cash flows for latest & last 40 quarters
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q4
Net Income Cash Flow
-19.92M-70.69M-58.86M-35.52M-16.64M-40.19M-25.52M-16.52M-7.18M-29.67M
Depreciation Depletion Amortization Cash-Flow-1.57M1.35M--1.3M1.01M--1.05M
Net Increase (Decrease) in Assets Liabilities66.3M-1.62M3.8M--1.11M-11.79M-9.99M-6.95M-4.12M56.41M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net2.08M9.39M7.19M3.67M3.06M8.2M5.1M3.56M1.45M13.5M
Net Cash from (used by) Operating Activities
48.61M-61.35M-46.51M-30.62M-14.29M-42.48M-29.39M-19.2M-9.48M41.29M
Increase (Decrease) in Prop Plant And Equipment-1.6M-3.98M-3.82M-3.41M-2.94M-5.02M-1.16M-0.65M-0.46M-1.03M
Acquisition Disposition of Subsidiaires----------
Increase (Decrease) in Investments60M-60.24M62.6M23.6M52.75M63.07M55.95M13M-193.73M
Other Cash Inflow (Outflow) from Investment Activities------0.42M-0.47M-0.47M-0.47M-
Net Cash from (used by) Investment Activities
58.4M-3.68M56.42M59.18M20.65M47.3M61.44M54.83M12.06M-194.76M
Issuance (Purchase) of Equity Shares1.82M59.92M1.65M1.1M-----177.74M
Issuance (Repayment) of Debt Securities----------
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities----------
Net Cash from (used by) Financing Activities
1.82M59.92M1.65M1.1M-----177.74M
Effect of Exchange Rate Changes on Cash----------
Net Change in Cash & Cash Equivalents
108.84M-5.11M11.56M29.65M6.96M5.33M32.19M35.72M2.58M24.27M
Cash & Equivalents at Beginning of Year36.64M31.3M7.03M-------
Cash & Equivalents at Year End141.1M31.53M48.2M66.3M43.6M36.64M63.5M67.03M33.89M31.3M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

While Voyager Therapeutics stock price history provides the price history of a stock, Voyager Therapeutics stock comparison chart shows the same in comparison to peers, and cash flow statements provide cash position of the company. Common terms used in the statement of cash flows are:

  • Voyager Therapeutics had a Net Change in Cash and Cash Equivalents of $108.84M in the latest quarter 2018 Q1. If a firm is able to grow its cash, it is considered to be a positive signal and could lead to a jump in the Voyager Therapeutics stock price, albeit too much cash on hand can imply the company has no or limited avenues for growth in which to invest this cash.
  • Voyager Therapeutics increased its cash from operating activities to $48.61M till 2018 Q1. Operating activities include production of goods or creating a product or providing a service, and collecting payment for the same from customers. The cash generated from these activities is refered to as cash flow from operating activities.
  • Cash Flow from investment activities: This includes buying/selling of land and equipment, acquisitions and mergers, sell-off, investment in other companies like buying bonds, stocks etc., and was $58.4M for VYGR till last quarter 2018 Q1 report.
  • Cash Flow from financing activities: The cash inflow/outflow from financing activities was $1.82M for Voyager Therapeutics. The money accounted for under this head comes from external sources which includes lenders, investors and shareholders. Positive cash flow is generated when the company gets cash because of issuance of stocks or bonds. Similarly negative cash flow is generated when shares are repurchased, dividend payments are made, and loans or interest on loans are paid back.

Key Financial Ratios For Voyager Therapeutics Cash Flow

FCF margin
50.01

Quarterly Cash Flow Statements For Voyager Therapeutics Inc Peers

Adamas Pharma cash flow, Biogen Inc cash flow, Ionis Pharma cash flow, PTC Therapeutics cash flow